Atlas Venture Fund XI, L.P.'s Form 4 filing
Sionna Therapeutics, Inc. (SION) · filed Feb 10, 2025
- Accession no.
- 0000950170-25-017030
- Filed
- Feb 10, 2025, 4:05 PM ET
- Trade date
- Feb 10, 2025
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 5 derivative transactions. Open-market purchases total $1.08M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Atlas Venture Fund XI, L.P.CIK 0001708269 | 10% Owner |
| Atlas Venture Associates XI, LLCCIK 0001780067 | 10% Owner |
| Atlas Venture Associates XI, L.P.CIK 0001780068 | 10% Owner |
| Atlas Venture Opportunity Fund II, L.P.CIK 0001885327 | 10% Owner |
| Atlas Venture Associates Opportunity II, LLCCIK 0001935810 | 10% Owner |
| Atlas Venture Associates Opportunity II, LPCIK 0001935814 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 10, 2025 | Common Stock | CConversionAcquired | +2,886,293 | –F1 | – | 2,886,293 | Direct | |
| Feb 10, 2025 | Common Stock | CConversionAcquired | +747,727 | –F1 | – | 747,727 | Indirect | |
| Feb 10, 2025 | Common Stock | PPurchaseAcquired | +60,000 | $18.00 | +$1,080,000 | 807,727 | Indirect | Duplicate filing |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 10, 2025 | Common Stock | CConversionDisposed | −719,355 | $0.00 | $0 | 0 | Direct | |
| Feb 10, 2025 | Common Stock | CConversionDisposed | −1,236,271 | $0.00 | $0 | 0 | Direct | |
| Feb 10, 2025 | Common Stock | CConversionDisposed | −888,599 | $0.00 | $0 | 0 | Direct | |
| Feb 10, 2025 | Common Stock | CConversionDisposed | −42,068 | $0.00 | $0 | 0 | Direct | |
| Feb 10, 2025 | Common Stock | CConversionDisposed | −747,727 | $0.00 | $0 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.
Referenced by the price of 2 transactions in Table I.
Remarks
4. Reflects shares purchased in the Issuer's initial public offering.